Companies Combine Best-in-Class Product Lines for Advanced Sequencing.
DENVILLE, N.J. (PRWEB) MARCH 05, 2020
Diagenode, a leading global provider of complete solutions for sample preparation and epigenetics research, and MGI Tech (MGI), a subsidiary of global genomics leader BGI Group, today announced a co-marketing agreement for Diagenode’s innovative NGS library preparation product line in the United States, Europe and Asia Pacific.
Under the terms of the non-exclusive agreement, the two companies have made Diagenode’s newest D-Plex Library Preparation products available on the MGI platform. MGI and Diagenode will market and promote Diagenode’s solutions for advanced epigenetic discoveries including the innovative D-Plex small RNA-sequencing technology, specifically formatted to work with MGI’s DNBSEQ™ sequencers using the appropriate MGI-compatible products.
“This agreement brings together our best-in-class and unique library preparation products and MGI’s high-quality cost-effective PCR-free sequencing solution, creating a combined platform to embrace the rapidly expanding markets in USA, Asia Pacific and Europe,” said Didier Allaer, CEO and founder of Diagenode. “This initiative brings premium epigenetics products to MGI’s customers, allowing them to experience exceptional performance and new discoveries.”
“This important collaboration leverages the strengths of both companies and provides an opportunity to extend our capabilities and advanced sequencing technology for our customers working in cancer, neurology, autoimmune disease and other genomic applications,” said Duncan Yu, president of MGI. “Demand is growing for MGI’s DNBSEQ™ platform with its high accuracy, affordability and applications within the marketplace. We look forward to a continued expansion of our offerings with leading products like the Diagenode D-Plex small RNA-sequencing solution specifically optimized with our platform.”
About MGI
MGI, a subsidiary of BGI Group, is committed to building core tools and technology to lead life science through intelligent innovation. Based on its proprietary technology, MGI produces sequencing instruments, reagents, equipment and related products to support life science research, agriculture, medicine and healthcare. MGI is a leading producer of clinical high-throughput gene sequencers, and its multi-omics platforms include sequencing, mass spectrometry, medical imaging and laboratory automation. Providing real-time, comprehensive, life-long solutions, its vision is to enable effective and affordable healthcare solutions for all.
About Diagenode Inc Corporation
Diagenode is a leading provider of complete solutions for epigenetics research and sample preparation. The company has developed both shearing solutions for a number of applications as well as a comprehensive approach to gain new insights into epigenetics studies. The company offers innovative DNA and chromatin shearing and automation instruments, reagent kits, and high quality antibodies to streamline DNA methylation, ChIP, and ChIP-seq workflows. The company’s latest innovations include the industry’s most validated ChIP antibodies, D-Plex RNA sequencing with UMIs, and epigenetics assay services including scATAC-seq. For more information about Diagenode, please visit the company’s website at http://www.diagenode.com.
